Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AZD7986 Alone and With Verapamil, Itraconazole or Diltiazem
NCT02653872Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2016
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brensocatib in bronchiectasis and chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by AstraZeneca. Primary endpoints: Maximum Plasma Concentration at Day 6, Area Under Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity at Day 6 and 6 more. Started Jan 2016; status: completed.
02
Drugs
brensocatib
03
Conditions
bronchiectasischronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02653872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02653872.